

SEOUL, KOREA GRAND WALKERHILL HOTEL,

MARCH 28 - 30, 2024

65th Annual Meeting 2024 KOREAN SOCIETY OF HEMATOLOGY INTERNATIONAL CONFERENCE &

ICK2H 505¢



www.icksh.org



Key Dates

DEC 29, 2023 **Abstract Submission** Deadline

JAN 19, 2024

Notification of Abstract Acceptance

FEB 28, 2024

Early-bird Registration Deadline

Venue

GRAND WALKERHILL SEOUL

- · 177 Walkerhill-ro Gwangjin-gu, Seoul, 143-708 Korea
- · Tel: +82-2-455-5000
- · Fax: +82-2-452-6867
- · Homepage: https://www.walkerhill.com/en/



ICKSH 2024 Secretariat

1F, Haeoreum B/D, 16, Yeoksam-ro 17 gil, Yeoksam-dong, Gangnam-gu, Seoul, Korea Tel. +82-2-566-5058 Fax. +82-2-566-6087 E-mail. icksh@icksh.org



hematopoietic stem cell niche How to win: Competitive strategies in the March 29 (Fri), 2024

Plenary Lecture 02



Peter J. Campbell (Wellcome Sanger Institute, UK)

Genomic science in human cancer and blood

March 28 (Thu), 2024 Plenary Lecture 01

Presidential Symposium O1

Chong H. Ahn (University of Cincinnati, USA) Lab-on-a-chip in hematology

PRESIDENTIAL SYMPOSIUM

PLENARY LECTURES Key Speakers

Program at a Glance

DATE	Thursday, March 28					Friday, March 29				DATE	Saturday, March 30				
ROOM	ROOM 1	ROOM 2	ROOM 3	ROOM 4	ROOM	ROOM 1	ROOM 2	ROOM 3	ROOM 4	ROOM	ROOM 1	ROOM 2	ROOM 3	ROOM 4	
08:00-	Registration					Danishashia a			07:30- 08:30	Business Meeting					
08:50- 09:00	Opening Remark				09:00		Registration			08:30- 09:00	Young Investigator Award Presentation				
09:00- 10:15	[JS01]	[SS01]	[SS02]	[ESO1]	09:00- 10:15	[JS03]	[SS09]	[SS10]	[ES03] *Kor	09:00- 10:15	[ES06] *Kor	[SS14]	[SS15]	[ES07] *Kor	
10:15- 10:30	Break					Break				10:15- 10:30	Break				
10:30- 11:15	[PLO1]					[PLO2]				10:30- 11:15	[PAP01]				
11:15- 12:00	[PS]					Poster Viewing				11:15- 11:45	Award Ceremony & Closing				
12:00- 12:15	Break					Break				Session Code [PS] Presidential Symposium [PL] Plenary Lecture					
12:15- 13:05	Luncheon Symposium					Luncheon Symposium									
13:05- 13:20	Break				13:05- 13:20	Break				[SS] Scientific Session [ES] Educational Session					
13:20- 14:50	[OP01]	[OP02]	[OP03]	[OP04]	13:20- 14:50	[OP05]	[OP06]	[OP07]	[OP08]	[JS	[JS] Joint Symposium				
14:50- 15:05	Break				14:50- 15:05	Break									
15:05- 16:20	[JS02]	[SS03]	[SS04]	[SS05]	15:05- 16:20	[JS04]	[SS11]	[SS12]	[ESO4]	* Scan QR Code below and access the congress website.					
16:20- 16:35	Break				16:20- 16:35	Break					* Updated lecture titles and speaker information can be found on the website.				
16:35- 17:50	[SS06]	[SS07]	[8082]	[ES02]	16:35- 17:50		[JS05]	[SS13]	[ESO5]		i tile website.				
17:50- 18:00	Break 17.3					Gala Reception				Š					
18:00-	Welcome Reception					Gala Dinner				Ö					

ICKSH 2024 Highlight Lectures

DAY 1. March 28 (Thu)

[SS01]

Molecular mechanism of primary TKI resistance in CML

Jerald Radich (Fred Hutchinson Cancer Center)

Targeting leukemic stem cells in CML Mhairi Copland (Univ. of Glasgow)

FSS021

Elucidating the 3D chromatin landscape of pediatric B-cell acute lymphoblastic leukemia using Micro-C

Kajsa Paulsson (Lund Univ.)

Leveraging dysregulated signaling networks for therapeutic benefit in MPN Stephen T. Oh (Washington Univ. School of Medicine)

[SS03]

Single cell technology in AML-single cell multi-omics

Manoj Bhasin (Emory Univ.)

Targeting the developmental heterogeneity of human acute myeloid leukemia Shanshan Pei (Zhejiang Univ.)

[SS04]

CAR T cells for treatment of T cell malignancies

Paul M. Maciocia (Cancer Research UK)

DAY 2. March 29 (Fri) -

FSS091

The impact of immune profiling of T and plasma cells on non-cellular immune therapy in myeloma

Nizar J Bahlis (Arnie Charbonneau Cancer Research Institute)

Single-cell techniques to characterize immune microenvironment in MM Niels Weinhold (Univ. Hosp Heidelberg)

[5510]

Clonal hematopoiesis and aging

Siddhartha Jaiswal (Stanford Univ. School of Medicine)

Clonal hematopoiesis: Implications for cell therapy

Adam S. Sperling (Dana-Farber Cancer Institute)

[SS11]

The role of blinatumomab in the treatment of MRD negative B-ALL in adults Mark R. Litzow (Mayo Clinic)

[SS12]

Long-term survivorship in hematologic malignancies Shahrukh K. Hashmi (Mayo Clinic)

[SS13]

Congenital and aquired thrombophilic conditions in children
Leonardo R. Brandão (Univ. of Toronto)

55051

Approaches to treat people with hemophilia: What's new and what's not? Leonard Valentino (NBDF)

Prospects and challenges of gene therapy Alok Srivastava (Christian Medical College)

ISS061

Molecular alterations and clinical implications in MDS

Yasushi Miyazaki (Nagasaki Univ.)

Recent advances and future the rapeutic strategies in $\ensuremath{\mathsf{MDS}}$

Garcia-Manero Guillermo (MD Anderson Cancer Center)

[SS07]

Germinal center in the genesis of lymphomas

Laura Pasqualucci (Columbia Univ.)

Genomics of follicular lymphoma: Clinical implications?

Robert Kridel (Univ. of Toronto)

[**SS**08]

RUNX1-FPD with predisposition to hematologic malignancies

Paul Liu (Bethesda)

Clinical impact of DDX41 mutations in myeloid neoplasms

Talha Badar (Mayo Clinic)

DAY 3. March 30 (Sat) -

[SS14]

 $\label{thm:matter} \mbox{Myeloproliferative neoplasms and inflammation}$

Steffen Koschmieder (RWTH Aachen University)

Signaling contributing to the development of myelofibrosis: Beyond JAK/STAT Douglas Tremblay (Mount Sinai School of Medicine)

[SS15]

 $Treatment\ options\ for\ relapsed/refractory\ hodgkin\ lymphoma\ after\ brentuximab\ vedotin\ and\ PD-1\ blockade$

Alex F. Herrera (City of Hope)

 $\label{prop:section} \mbox{Aggressive B-cell lymphomas: Immuno-chemotherapies other than CAR-T the rapies} \mbox{ Jason Westin (MD Anderson Cancer Center)}$